Compare Glenmark Pharma with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs ASTRAZENECA PHARMA - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA ASTRAZENECA PHARMA GLENMARK PHARMA/
ASTRAZENECA PHARMA
 
P/E (TTM) x 15.7 121.6 12.9% View Chart
P/BV x 2.2 35.6 6.1% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 GLENMARK PHARMA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
ASTRAZENECA PHARMA
Mar-18
GLENMARK PHARMA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs7121,278 55.7%   
Low Rs484883 54.8%   
Sales per share (Unadj.) Rs349.6228.4 153.1%  
Earnings per share (Unadj.) Rs32.810.4 316.3%  
Cash flow per share (Unadj.) Rs44.316.3 272.6%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs198.698.8 201.1%  
Shares outstanding (eoy) m282.1725.00 1,128.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.74.7 36.1%   
Avg P/E ratio x18.2104.2 17.5%  
P/CF ratio (eoy) x13.566.4 20.3%  
Price / Book Value ratio x3.010.9 27.5%  
Dividend payout %6.10-   
Avg Mkt Cap Rs m168,62527,008 624.4%   
No. of employees `00012.01.4 887.7%   
Total wages/salary Rs m20,5611,535 1,339.2%   
Avg. sales/employee Rs Th8,196.04,210.9 194.6%   
Avg. wages/employee Rs Th1,708.11,132.2 150.9%   
Avg. net profit/employee Rs Th768.5191.1 402.2%   
INCOME DATA
Net Sales Rs m98,6555,710 1,727.8%  
Other income Rs m2,081123 1,699.1%   
Total revenues Rs m100,7365,833 1,727.2%   
Gross profit Rs m15,858463 3,425.8%  
Depreciation Rs m3,259147 2,211.1%   
Interest Rs m3,3460-   
Profit before tax Rs m11,335438 2,587.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,6720-   
Tax Rs m3,756179 2,099.7%   
Profit after tax Rs m9,250259 3,570.0%  
Gross profit margin %16.18.1 198.3%  
Effective tax rate %33.140.8 81.1%   
Net profit margin %9.44.5 206.6%  
BALANCE SHEET DATA
Current assets Rs m66,9683,209 2,086.8%   
Current liabilities Rs m40,2112,070 1,943.0%   
Net working cap to sales %27.120.0 135.9%  
Current ratio x1.71.6 107.4%  
Inventory Days Days8372 115.2%  
Debtors Days Days8135 232.5%  
Net fixed assets Rs m33,322790 4,216.3%   
Share capital Rs m28250 564.4%   
"Free" reserves Rs m55,7702,419 2,305.2%   
Net worth Rs m56,0522,469 2,269.9%   
Long term debt Rs m35,7380-   
Total assets Rs m132,8884,605 2,885.5%  
Interest coverage x4.4NM-  
Debt to equity ratio x0.60-  
Sales to assets ratio x0.71.2 59.9%   
Return on assets %9.55.6 168.5%  
Return on equity %16.510.5 157.3%  
Return on capital %17.817.7 100.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m62,998300 21,031.0%   
Fx outflow Rs m22,8592,015 1,134.5%   
Net fx Rs m40,140-1,715 -2,340.0%   
CASH FLOW
From Operations Rs m13,24288 15,064.5%  
From Investments Rs m-6,990-94 7,467.8%  
From Financial Activity Rs m-7,387NA-  
Net Cashflow Rs m-2,971-6 52,119.3%  

Share Holding

Indian Promoters % 48.3 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 6.9 0.3 2,300.0%  
FIIs % 34.4 15.7 219.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 9.1 115.4%  
Shareholders   56,727 12,856 441.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  WOCKHARDT  GSK PHARMA  PANACEA BIOTECH  

Compare GLENMARK PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 178 Points Higher; Telecom and Power Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest throughout the day today and ended on a positive note.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

Be Prepared to Profit from the Coming Crash in Oil Prices(Fast Profits Daily)

Jun 25, 2020

The stability in crude oil prices will not last much longer. Be ready to make fast profits when the time comes to short crude.

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Tata Motors Tripled in 18 Months but You Can Do Even Better. Here's How...(Profit Hunter)

Jun 24, 2020

Rahul is ready for a repeat of his famous 2008 Tata Motors call.

This Ratio Says Smallcaps Are Your Best Bet to Ride the Post Covid Market Rebound(Profit Hunter)

Jun 23, 2020

Here's why I believe that post Covid rebound in smallcaps will be much sharper than largecaps.

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jul 3, 2020 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - DISHMAN PHARMA COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS